Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

US11807649B2 · kind B2 · utility

Assignee

• EnLiven Therapeutics, Inc. · US

Inventors

• Joseph P. Lyssikatos · South San Francisco, US
• Samuel Kintz · Boulder, US
• Li Ren · Superior, US
• Qiang Su · Chengdu, CN

Key dates

• Filing date: Nov 1, 2022
• Grant date: Nov 7, 2023
• Expiry date: Dec 24, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.